SLXN Silexion Therapeutics Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2022416 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-43.1%
TTM EPS YoY-211.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-266.0%
ROA-143.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets56.5%
Debt / equity0.00x
Current ratio1.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.29M | $2.21M | $1.37M | $3.38M | $2.16M | $1.02M | $590,000 | $871,000 |
| SG&A expense | $1.40M | $1.47M | $1.38M | $1.03M | $1.14M | $1.27M | $1.06M | $1.03M |
| Operating income | -$2.68M | -$3.68M | -$2.75M | -$4.41M | -$3.29M | -$2.28M | -$1.65M | -$1.90M |
| Pretax income | -$2.53M | -$3.55M | -$2.73M | -$4.41M | -$3.26M | -$2.50M | -$1.74M | -$1.75M |
| Income tax | — | — | — | $0 | $0 | $3,000 | — | $1,000 |
| Net income | -$2.53M | -$3.55M | -$2.73M | -$4.41M | -$3.26M | -$2.50M | -$1.74M | -$1.75M |
| EBITDA | -$2.68M | -$3.68M | -$2.75M | -$4.40M | -$3.29M | -$2.28M | -$1.65M | -$1.91M |
| EPS (basic) | 13.70 | 5.17 | 0.85 | — | 691.14 | 43.19 | 3.84 | — |
| EPS (diluted) | 13.70 | 5.17 | 0.85 | — | 691.14 | 43.19 | 3.84 | — |
| Weighted avg. shares (diluted) | 184,927 | 687,353 | 3.23M | — | 4,720 | 57,952 | 451,990 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.76M | $2.32M | $2.50M | $5.99M | $9.32M | $3.54M | $6.23M | $1.27M |
| Current assets | $6.11M | $3.74M | $4.07M | $6.64M | $11.05M | $5.24M | $7.72M | $2.25M |
| PP&E, net | $21,000 | $20,000 | $23,000 | $25,000 | $26,000 | $30,000 | $32,000 | $30,000 |
| Total assets | $6.83M | $4.25M | $4.60M | $7.21M | $11.61M | $5.80M | $8.31M | $2.86M |
| Current liabilities | $3.68M | $3.98M | $4.06M | $2.76M | $2.79M | $2.15M | $2.40M | $3.52M |
| Total liabilities | $3.86M | $4.20M | $4.31M | $4.61M | $4.64M | $5.68M | $5.72M | $6.85M |
| Shareholders' equity | $2.97M | $44,000 | $291,000 | $2.60M | $6.98M | $120,000 | $2.59M | -$3.99M |
| Shares outstanding | 603,055 | 1.18M | 3.13M | 13,028 | 3.13M | 579,536 | 8.69M | 123.29M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.11M | -$2.92M | -$3.65M | -$3.02M | -$2.84M | -$2.51M | -$2.45M | -$2.93M |
| Capital expenditure | $42,000 | $0 | $0 | $2,000 | $0 | $1,000 | $6,000 | $0 |
| Free cash flow | -$2.15M | -$2.92M | -$3.65M | -$3.02M | -$2.84M | -$2.51M | -$2.46M | -$2.93M |
| Investing cash flow | -$42,000 | -$1,000 | $0 | -$7,000 | $0 | -$1,000 | -$6,000 | $0 |
| Financing cash flow | $4.70M | $2.74M | $83,000 | -$221,000 | $8.62M | -$195,000 | $7.43M | $2.18M |
| Depreciation & amortization | $2,000 | $3,000 | $2,000 | $3,000 | $4,000 | $3,000 | $4,000 | -$12,000 |
| Stock-based compensation | $16,000 | $197,000 | $345,000 | $38,000 | $38,000 | $37,000 | $21,000 | $0 |
Free plan shows the latest 8 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.